Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VP1-targeting small molecule
- Development stage
- Preclinical
- Lead developer
- Orthogon Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VP1-targeting small molecule is a first-in-class, orally available small-molecule antiviral candidate being developed by Orthogon Therapeutics (an affiliate of Pledge Therapeutics) for the treatment and prophylaxis of BK polyomavirus (BKPyV) and JC polyomavirus (JCPyV) infections, particularly in immunocompromised transplant recipients. The drug works by binding with high affinity to a highly conserved intracellular site on the viral capsid protein VP1, distinct from the variable antibody-binding cleft. This binding alters capsid architecture and blocks viral replication, providing pan-genotypic activity across BKPyV subtypes and JCPyV. The candidate is designed to penetrate renal sanctuaries of viral replication and maintain stability in urine, offering a high genetic barrier to resistance and avoiding the limitations of monoclonal antibodies.
- Other names
- anti-Polyomavirus drugBK virus antiviral drugBKPyV VP1-targeting small molecule
02
Targets
Norovirus VP1JCV (John Cunningham virus)
Beyond the preview
Go deeper on VP1-targeting small molecule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VP1-targeting small molecule.